Access the full text.
Sign up today, get DeepDyve free for 14 days.
Rachel Yamnik, A. Digilova, D. Davis, Z. Brodt, C. Murphy, M. Holz (2009)S6 Kinase 1 Regulates Estrogen Receptor (cid:1) in Control of Breast Cancer Cell Proliferation *
J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, K. Hazell, E. Martinelli, S. Cajal, Suzanne Jones, L. Vidal, N. Shand, T. Macarulla, F. Ramos, S. Dimitrijević, U. Zoellner, Pui Tang, M. Stumm, H. Lane, D. Lebwohl, J. Baselga (2008)Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 10
W. Gradishar, B. Anderson, R. Balassanian, S. Blair, H. Burstein, Amy Cyr, A. Elias, W. Farrar, A. Forero, S. Giordano, M. Goetz, L. Goldstein, C. Hudis, S. Isakoff, P. Marcom, I. Mayer, B. McCormick, M. Moran, Sameer Patel, L. Pierce, E. Reed, K. Salerno, L. Schwartzberg, K. Smith, M. Smith, H. Soliman, G. Somlo, M. Telli, J. Ward, Dorothy Shead, Rashmi Kumar (2016)Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN, 14 3
Rachel Yamnik, M. Holz (2010)mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation
FEBS Letters, 584
J. Baselga, M. Campone, M. Piccart, H. Burris, H. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. Pritchard, F. Lebrun, J. Beck, Yoshinori Ito, D. Yardley, I. Deleu, Alejandra Perez, T. Bachelot, L. Vittori, Zhi-Xia Xu, P. Mukhopadhyay, D. Lebwohl, G. Hortobagyi (2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
The New England journal of medicine, 366 6
G. Kirchner, Ivo Meier-Wiedenbach, M. Manns (2004)Clinical Pharmacokinetics of Everolimus
Clinical Pharmacokinetics, 43
W. Gradishar, B. Anderson, R. Balassanian, S. Blair, H. Burstein, Amy Cyr, A. Elias, W. Farrar, A. Forero, S. Giordano, M. Goetz, L. Goldstein, C. Hudis, S. Isakoff, P. Marcom, I. Mayer, B. McCormick, M. Moran, Sameer Patel, L. Pierce, E. Reed, K. Salerno, Lee Schwartzberg, K. Smith, Mary Smith, H. Soliman, G. Somlo, M. Telli, J. Ward, Dorothy Shead, Rashmi Kumar (2016)Invasive breast cancer version 1.2016
Journal of The National Comprehensive Cancer Network, 14
E. Paplomata, R. O'Regan (2014)The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Therapeutic Advances in Medical Oncology, 6
A. Pilotte, Melissa Hohos, Kathleen Polson, T. Huftalen, N. Treister (2011)Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.
Clinical journal of oncology nursing, 15 5
F. Martins, M. Oliveira, Qian Wang, S. Sonis, M. Gallottini, S. George, N. Treister (2013)A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.
Oral oncology, 49 4
H. Rugo, G. Hortobagyi, J. Yao, M. Pavel, A. Ravaud, D. Franz, F. Ringeisen, J. Gallo, N. Rouyrre, O. Anak, R. Motzer (2016)Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
Annals of Oncology, 27
F. André, S. Hurvitz, A. Fasolo, L. Tseng, G. Jerusalem, S. Wilks, R. O'Regan, C. Isaacs, M. Toi, H. Burris, Wei He, D. Robinson, Markus Riester, T. Taran, David Chen, D. Slamon (2016)Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 18
E. Paplomata, A. Zelnak, R. O'Regan (2013)Everolimus: side effect profile and management of toxicities in breast cancer
Breast Cancer Research and Treatment, 140
L. Moscetti, P. Vici, T. Gamucci, C. Natoli, E. Cortesi, P. Marchetti, D. Santini, R. Giuliani, I. Sperduti, M. Mauri, L. Pizzuti, M. Mancini, M. Fabbri, V. Magri, L. Iezzi, V. Sini, L. D’Onofrio, L. Mentuccia, A. Vaccaro, S. Ramponi, C. Roma, E. Ruggeri (2016)Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
M. Aapro, F. André, K. Blackwell, E. Calvo, M. Jahanzeb, K. Papazisis, C. Porta, K. Pritchard, A. Ravaud (2014)Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 4
Rachel Yamnik, A. Digilova, D. Davis, Z. Brodt, Christopher Murphy, M. Holz (2009)S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation*
Journal of Biological Chemistry, 284
(2016)Prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor–positive metastatic breast cancer using a dexamethasone-based mouthwash: results of the SWISH Trial
S. Hurvitz, F. André, Zefei Jiang, Z. Shao, M. Mano, S. Neciosup, L. Tseng, Qingyuan Zhang, K. Shen, Donggeng Liu, L. Dreosti, H. Burris, M. Toi, M. Buyse, David Cabaribere, M. Lindsay, S. Rao, L. Pacaud, T. Taran, D. Slamon (2015)Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
The Lancet. Oncology, 16 7
Mary Peterson (2013)Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
Supportive Care in Cancer, 21
(2015)Results of the third interim analysis of the non-interventional trial BRAWO—subanalysis of patients aged 70 years and 70 years
J. Baselga, V. Semiglazov, P. Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, J. Steinseifer, B. Molloy, E. Tokaji, H. Gardner, P. Phillips, M. Stumm, H. Lane, J. Dixon, W. Jonat, H. Rugo (2009)Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 16
R. Motzer, B. Escudier, S. Oudard, Thomas Hutson, F. Group (2008)Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
The Lancet, 372
J. Stockman (2012)Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yearbook of Pediatrics, 2012
K. Pritchard, H. Burris, Yoshinori Ito, H. Rugo, S. Dakhil, G. Hortobagyi, M. Campone, T. Csöszi, J. Baselga, P. Puttawibul, M. Piccart, D. Heng, S. Noguchi, V. Srimuninnimit, H. Bourgeois, A. Martín, K. Osborne, A. Panneerselvam, T. Taran, T. Sahmoud, M. Gnant (2013)Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Clinical breast cancer, 13 6
H. Wildiers, I. Kunkler, L. Biganzoli, J. Fracheboud, G. Vlastos, C. Bernard‐Marty, A. Hurria, M. Extermann, V. Girre, E. Brain, R. Audisio, H. Bartelink, M. Barton, S. Giordano, H. Muss, M. Aapro (2007)Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.
The Lancet. Oncology, 8 12
Y. Im, R. Uslu, K. Lee, R. Nagarkar, J. Sohn, A. Sevinç, K. Altundağ, Yuan-Ching Chang, H. Abdel-Razeq, S. Im, Joon Jeong, H. Park, W. Arpornwirat, P. Bastick, T. Le, O. Arikan, H. Xue, A. Canatar, R. Valenti, Sung-Bae Kim (2015)Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.
Journal of Clinical Oncology, 33
N. Busaidy, A. Farooki, A. Dowlati, J. Perentesis, J. Dancey, L. Doyle, J. Brell, L. Siu (2012)Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 23
M. Piccart, G. Hortobagyi, M. Campone, K. Pritchard, F. Lebrun, Yoshinori Ito, S. Noguchi, Alejandra Perez, H. Rugo, I. Deleu, H. Burris, L. Provencher, P. Neven, M. Gnant, M. Shtivelband, C. Wu, Jenna Fan, W. Feng, T. Taran, J. Baselga (2014)Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 12
S. Ellard, M. Clemons, K. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, Marianne Taylor, E. Sauerbrei, M. Mishaeli, D. Huntsman, W. Walsh, M. Olivo, L. Mcintosh, L. Seymour (2009)Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J. Ferrero, G. Freyer, S. Abadie-Lacourtoisie, J. Eymard, M. Debled, D. Spaëth, E. Legouffe, D. Allouache, C. Kouri, E. Pujade-Lauraine (2012)Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 22
A. Act (2014)Breast Cancer: Basic and Clinical Research
(2016)Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy
(2010)Management of key adverse events associated with everolimus therapy
D. Lueftner, F. Schuetz, E. Grischke, P. Fasching, P. Wimberger, F. Foerster, T. Decker, C. Uleer, M. Muth, J. Kreuzeder, W. Bloch, H. Tesch, C. Jackisch (2014)Breast cancer treatment with everolimus and exemestane for ER+ women: Results of the first interim analysis of the noninterventional trial BRAWO.
Journal of Clinical Oncology, 32
H. Burris, F. Lebrun, H. Rugo, J. Beck, M. Piccart, P. Neven, J. Baselga, K. Petráková, G. Hortobagyi, A. Komorowski, E. Chouinard, R. Young, M. Gnant, K. Pritchard, L. Bennett, J. Ricci, H. Bauly, T. Taran, T. Sahmoud, S. Noguchi (2013)Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial
G. Jerusalem, G. Mariani, E. Ciruelos, Miguel Martín, V. Tjan-Heijnen, P. Neven, J. Gavilá, A. Michelotti, F. Montemurro, D. Generali, E. Simoncini, I. Láng, J. Mardiak, B. Naume, B. Naume, M. Camozzi, K. Lorizzo, S. Bianchetti, P. Conte (2016)Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Annals of oncology : official journal of the European Society for Medical Oncology, 27 9
(2016)Available at: https://clinicaltrials.gov/ct2/show/NCT01698918
(2014)Subgroup analysis of efficacy in routine treatment—results of the 2nd interim analysis of BRAWO, the noninterventional trial “breast cancer treatment with everolimus and exemestane for HR+ women
D. Yardley, S. Noguchi, K. Pritchard, H. Burris, J. Baselga, M. Gnant, G. Hortobagyi, M. Campone, B. Pistilli, M. Piccart, B. Melichar, K. Petráková, F. Arena, F. Erdkamp, W. Harb, W. Feng, A. Cahana, T. Taran, D. Lebwohl, H. Rugo (2013)Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Advances in Therapy, 30
D. Nathan (2009)Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, 32
H. Rugo, K. Pritchard, M. Gnant, S. Noguchi, M. Piccart, G. Hortobagyi, J. Baselga, Alejandra Perez, M. Geberth, T. Csőszi, E. Chouinard, V. Srimuninnimit, P. Puttawibul, J. Eakle, W. Feng, H. Bauly, M. El-Hashimy, T. Taran, H. Burris (2014)Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
Annals of Oncology, 25
F. Cardoso, A. Costa, L. Norton, E. Senkus, M. Aapro, F. André, C. Barrios, J. Bergh, L. Biganzoli, K. Blackwell, M. Cardoso, T. Čufer, N. Saghir, L. Fallowfield, D. Fenech, P. Francis, K. Gelmon, S. Giordano, J. Gligorov, A. Goldhirsch, N. Harbeck, N. Houssami, C. Hudis, B. Kaufman, I. Krop, S. Kyriakides, U. Lin, M. Mayer, S. Merjaver, E. Nordström, O. Pagani, A. Partridge, F. Penault-Llorca, M. Piccart, H. Rugo, G. Sledge, C. Thomssen, L. Veer, D. Vorobiof, C. Vrieling, N. West, Bing-he Xu, E. Winer (2014)ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
Annals of Oncology, 25
F. André, R. O'Regan, M. Ozguroglu, M. Toi, Bing-he Xu, G. Jerusalem, N. Masuda, S. Wilks, F. Arena, C. Isaacs, Y. Yap, Z. Pápai, I. Láng, A. Armstrong, G. Lerzo, M. White, K. Shen, J. Litton, David Chen, Yufen Zhang, S. Ali, T. Taran, L. Gianni (2014)Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
The Lancet. Oncology, 15 6
(2010)Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
P. Fasching, T. Decker, A. Schneeweiss, C. Uleer, F. Förster, P. Wimberger, C. Kurbacher, N. Harbeck, O. Tomé, B. Müller, C. Mundhenke, S. Kümmel, M. Muth, J. Kreuzeder, Wilhelm Bloch, H. Tesch, D. Lüftner, C. Jackisch, F. Schütz, E. Grischke (2014)LBA9BREAST CANCER TREATMENT WITH EVEROLIMUS AND EXEMESTANE FOR ER+ WOMEN - RESULTS OF THE 2ND INTERIM ANALYSIS OF THE NON-INTERVENTIONAL TRIAL BRAWO
Annals of Oncology, 25
J. Kovarik, H. Sabia, Joaquim Figueiredo, H. Zimmermann, C. Reynolds, S. Dilzer, K. Lasseter, C. Rordorf (2001)Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment
Clinical Pharmacology & Therapeutics, 70
Everolimus combined with exemestane is an important treatment option for patients suffering from estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer (ABC) who have been previously treated with a nonsteroidal aromatase inhibitor (NSAI). After presentation of phase III registration trial BOLERO-2, several phase IIIb trials have been started to evaluate this regimen in a more real-world setting. Here, we review the efficacy and safety data published or presented at selected international meetings. These studies confirmed the outcome observed in the BOLERO-2 trial. Patient acceptance rate is also discussed by focusing on the permanent everolimus discontinuation rate in these trials. Factors influencing the safety profile are also reported, including the impact of age. The optimal sequence of combined therapy approaches associating targeted and endocrine therapy (ET) has yet to be determined as new treatment options such as cyclin-dependent kinase inhibitors become available. However, everolimus–exemestane remains an important treatment option with a major impact on progression-free survival (PFS) and an acceptable safety profile.
Breast Cancer: Basic and Clinical Research – SAGE
Published: Jan 4, 2017
Keywords: breast cancer; treatment; everolimus; safety; efficacy; progression-free survival
Access the full text.
Sign up today, get DeepDyve free for 14 days.